Advertisement
AXON vs BNTX
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. BioNTech (BNTX) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) boasts strong revenue growth of 39% in Q4 2025 and a positive 27-30% forecast for 2026, driven by software and services, contrasting BNTX's ongoing net losses amid oncology pipeline advancements.
- AXON year-to-date performance stands at approximately +29%, outperforming BNTX's +2% gain, though both have experienced recent pullbacks.
- BNTX benefits from positive Phase 2 trial data for its T-Pam cancer therapy, leading to analyst price target hikes to $130, while AXON highlights AI-powered public safety innovations.
- Upcoming Q1 2026 earnings for both—May 6 for AXON and May 5 for BNTX—could drive sentiment shifts in the near term.
- AXON's positive EPS of $1.53 and PE ratio (price-to-earnings ratio) of 263 reflect growth premium, versus BNTX's negative EPS of -$5.51.
Introduction
This stock comparison pits Axon Enterprise (AXON), a leader in public safety technology, against BioNTech SE (BNTX), a biotech innovator in mRNA therapies. Investors seeking exposure to high-growth sectors—industrials with recurring software revenue versus healthcare with clinical catalysts—may find value in evaluating their relative performance. Amid recent market volatility, both stocks have shown resilience yet face near-term catalysts like earnings reports. Traders focused on momentum and long-term investors eyeing stability can use this analysis to assess positioning in the current environment, where tech stability meets biotech upside potential. (102 words)
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops TASER devices, body cameras, and cloud-based software for law enforcement and public safety. In recent quarters, the company reported Q4 2025 revenue of $797 million, up 39% year-over-year, with software and services surging 40%. This growth, fueled by recurring annual recurring revenue (ARR), has bolstered sentiment despite a stock pullback in recent weeks amid broader market concerns and comparisons to high-flying AI peers. Trading around $402 with a $32.4 billion market cap, AXON forecasts 27-30% revenue expansion for 2026. Innovations like the AI-powered 911 platform have reinforced its competitive moat, though elevated PE ratio (price-to-earnings ratio) of 263 signals growth expectations. Year-to-date gains near 29% reflect underlying strength, tempered by 1-month dips of about 3%.
BNTX Overview and Recent Performance
BioNTech SE (BNTX) specializes in mRNA-based immunotherapies, transitioning from COVID-19 vaccines to oncology pipelines. Recent market activity highlights positive Phase 2 data for its antibody-drug conjugate T-Pam in endometrial cancer, sparking a 9% stock surge and analyst upgrades with $130 price targets. Trading near $98 with a $24.7 billion market cap, BNTX holds substantial cash reserves of $13.7 billion but reports TTM net losses with EPS of -$5.51. Sentiment has been volatile, with 1-month gains of 7% offset by a 6% drop in early May. Year-to-date up modestly at 2%, the stock anticipates Q1 2026 results amid pipeline progress in cancer and infectious diseases, driving trader interest despite profitability challenges.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 performers from over 351 AI trading bots, each employing diverse strategies like trend following, swing trading, and multi-agent risk management across timeframes from 5 minutes to days. These bots target sectors including semiconductors, space, and industrials, with annualized returns ranging from +24% to +163%, win rates of 51% to 88%, and profit factors up to 11.7. Examples include high performers on tickers like NVDA and ASTS, highlighting adaptive AI for volatile markets. Explore these curated bots suited to current conditions for potential edge in stock trading. (112 words)
Head-to-Head Comparison
Axon Enterprise (AXON) and BioNTech (BNTX) diverge sharply in business models: AXON leverages hardware-software synergies with high-margin recurring revenue (ARR), while BNTX relies on R&D milestones and clinical approvals. Growth drivers contrast AXON’s consistent 30%+ forecasts against BNTX’s binary pipeline events. Recent momentum shows AXON’s stability amid pullbacks versus BNTX’s trial-fueled surges but higher volatility. Risk factors include AXON’s elevated valuation and competition, and BNTX’s losses and regulatory hurdles. Sector exposure pits industrials resilience against biotech sensitivity, with market sentiment favoring AXON’s profitability edge.
Tickeron AI Verdict
Tickeron’s AI analysis leans toward AXON in the current environment, citing superior trend consistency, positive EPS, and reliable growth catalysts over BNTX’s higher-risk pipeline dependence. While BNTX offers breakout potential from clinical wins, AXON’s stability and outperformance position it as the probabilistic favorite for momentum traders ahead of earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and BNTX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBNTX’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BNTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while BNTX’s TA Score has 3 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 4 bearish.
- BNTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +8.33% price change this week, while BNTX (@Biotechnology) price change was -8.20% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -8.63%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was +23.70%.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -7.98%, and the average quarterly price growth was -1.75%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BNTX is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Aerospace & Defense (-8.63% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BNTX | AXON / BNTX | |
| Capitalization | 39.2B | 22.3B | 176% |
| EBITDA | 320M | -697.7M | -46% |
| Gain YTD | -14.405 | -7.479 | 193% |
| P/E Ratio | 196.02 | 161.76 | 121% |
| Revenue | 2.98B | 2.81B | 106% |
| Total Cash | 737M | 14.6B | 5% |
| Total Debt | 1.83B | 303M | 603% |
AXON | BNTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 60 | 100 | |
SMR RATING 1..100 | 82 | 94 | |
PRICE GROWTH RATING 1..100 | 48 | 72 | |
P/E GROWTH RATING 1..100 | 48 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (2) in the null industry is significantly better than the same rating for AXON (81) in the Biotechnology industry. This means that BNTX’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for BNTX (100) in the null industry. This means that AXON’s stock grew somewhat faster than BNTX’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as BNTX (94) in the null industry. This means that AXON’s stock grew similarly to BNTX’s over the last 12 months.
AXON's Price Growth Rating (48) in the Biotechnology industry is in the same range as BNTX (72) in the null industry. This means that AXON’s stock grew similarly to BNTX’s over the last 12 months.
BNTX's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for AXON (48) in the Biotechnology industry. This means that BNTX’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | BNTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 80% |
| MACD ODDS (%) | N/A | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 78% |
| Advances ODDS (%) | 5 days ago 74% | 9 days ago 70% |
| Declines ODDS (%) | 12 days ago 69% | 4 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 60% | N/A |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 82% |
Advertisement
BNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To BNTX | 1D Price Change % | ||
|---|---|---|---|---|
| BNTX | 100% | -1.69% | ||
| MRNA - BNTX | 47% Loosely correlated | -8.04% | ||
| AXON - BNTX | 43% Loosely correlated | -5.28% | ||
| VERA - BNTX | 39% Loosely correlated | -3.33% | ||
| RZLT - BNTX | 37% Loosely correlated | -5.65% | ||
| KYMR - BNTX | 36% Loosely correlated | -0.64% | ||
More | ||||